Protalix Biotherapeutics, Inc.

290 articles about Protalix Biotherapeutics, Inc.

• Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases

  7/23/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it has entered into a non-binding term sheet with SarcoMed USA Inc.

• Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development

  6/8/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX) today announced the appointment of Yael Hayon, Ph.D. as the Company's new Vice President, Research and Development, effective July 5, 2020. On June 2, 2020, Yoseph Shaaltiel, Ph.D. retired from his position as the Company's Executive Vice President, Research and Development, effective June 15, 2020.

• Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update

  6/1/2020

  Conference call and live webcast scheduled for Monday, June 1st, 2020 at 8:30 am EDT

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

  5/28/2020

  Protalix BioTherapeutics, Inc. together with Chiesi Global Rare Diseases announced the submission on May 27, 2020 of a Biologics License Application to the U.S. Food and Drug Administration for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease via the FDA's Accelerated Approval pathway.

• Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020

  5/22/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expres

• 

  Clinical Catch-Up: May 11-15

  5/18/2020

  Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

• Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

  5/11/2020

  Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced positive topline results from its Phase III BRIDGE clinical trial of pegunigalsidase alfa, or PRX-102.

• Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement

  3/18/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it has completed a $43.7 million private placement of common stock and warrants

• Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein

  3/16/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), announced today that it has agreed to conduct a feasibility study with Kirin Holdings Company, Limited (Kirin) to evaluate the production of a novel complex protein utilizing ProCellEx

• Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease

  3/12/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it has successfully secured securities purchase agreements, or the Purchase Agreements, to raise $43.7 million through a private equity investment (PIPE) in the Company.

• Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020

  3/5/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for fourth quarter and full-year 2019 and business update on Thursday, March 12, 2020.

• Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium™ 2020

  2/10/2020

  Phase I/II dose-ranging studies show high correlation between two Fabry disease biomarkers, supporting potential effectiveness of pegunigalsidase alfa in treating Fabry disease

• Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease

  2/6/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chiesi Farmaceutici S.p.A.

• Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

  2/4/2020

  Corporate presentation and live webcast at 2020 BIO CEO & Investor Conference scheduled for Monday, February 10, 2020 at 4:00 PM ET Corporate presentation and live webcast at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference scheduled for Monday,

• Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium™ 2020

  1/30/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), today announced that it will deliver an oral presentation and three poster presentations on its pegunigalsidase alfa candidate for the treatment of Fabry disease at the 16th Annual WORLDSymposium™ 2020

• Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors

  12/19/2019

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the appointment of Pol F. Boudes, MD, and Gwen A. Melincoff to its Board of Directors,

• Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split

  12/9/2019

  The 1‑for-10 reverse stock split of the Company's common stock is scheduled to become effective at midnight, December 19, 2019.

• Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease

  11/27/2019

   Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will host a key opinion leader (KOL) meeting on pegunigalsidase alfa, or PRX‑102

• Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

  11/18/2019

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), today announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX‑102) for the treatment of Fabry disease.

• Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

  11/7/2019

  Protalix BioTherapeutics, Inc. announced its third quarter 2019 financial results and provided a corporate update.